Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
| Degron Therapeutics | Shanghai | Series A | $40.0M | 2026-05-14 |
| OrphAI Therapeutics | Guilford | Series C | $58.0M | 2017-03-30 |
| Allink Biotherapeutics | Shanghai | Series A | $47.0M | 2025-12-16 |
| AccuPulse | Suzhou | Series B | $14.5M | 2026-03-13 |
| IMPACT Therapeutics | Nanjing | Series D | $34.6M | 2024-11-15 |
| Essentia Biosciences | Haidian | Seed | $14.3M | 2026-01-01 |
| Changmugu Medical | Beijing | Series B | $84.5M | 2021-11-10 |
8 rows of the CSV in 5 of its 18 columns.
- The 21 BioVenture portfolio companies have raised $935.4M in total.
- 5 of them closed their most recent round in the last 12 months, $235.8M combined.
- The largest of those rounds is AusperBio's $120.0M Series C, dated August 2026.
- Qiming Venture Partners is an investor in 2 of them, more than any other fund.
- Health care is the most common sector, with 20 companies (95%).
- 29% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (39% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
8 of 21| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Shanghai, China | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
| AccuPulse | AccuPulse develops pulsed electric field ablation generators and catheters. | Health care | Suzhou, China | Series B | $14.5M | 2026-03-13 | $72.5M | BioVenture, Shanghai Biomedical Industrial Equity Investment Fund, Med-Fine Capital +1 | 11 to 50 | 2020 |
| Essentia Biosciences | Essentia Biosciences develops cell therapies, gene technology drugs, and medical devices. | Biotech | Haidian, China | Seed | $14.3M | 2026-01-01 | $14.3M | BioVenture, Haitang Fund, Beijing Molecular Technology | 1 to 10 | 2021 |
| Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Shanghai, China | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| IMPACT Therapeutics | IMPACT Therapeutics develops similar drugs to treat cancer. | Biotech | Nanjing, China | Series D | $34.6M | 2024-11-15 | BioVenture, Lilly Asia Ventures, Decheng Capital +2 | 51 to 100 | 2009 | |
| Changsha Morning Shine | Changsha Morning Shine is a pharmaceutical company offering CDMO, chemical drug, and biotechnology services. | Biotech | Changshan, China | Series A | $14.1M | 2023-12-14 | $14.1M | BioVenture, Jolmo Capital, Sunz Fund | 2019 | |
| Gachun Biotech | Gachun Biotech runs an industrial platform producing active pharmaceutical ingredients and pharmaceutical intermediates. | Biotech | Chengdu, China | Series A | $14.1M | 2023-11-23 | $14.1M | BioVenture, Si Chuan Venture Capital | 11 to 50 | 2017 |
Table 1. BioVenture portfolio companies: the 8 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 21.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 2 | Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Shanghai, China | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| 3 | Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Shanghai, China | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
| 4 | AccuPulse | AccuPulse develops pulsed electric field ablation generators and catheters. | Health care | Suzhou, China | Series B | $14.5M | 2026-03-13 | $72.5M | BioVenture, Shanghai Biomedical Industrial Equity Investment Fund, Med-Fine Capital +1 | 11 to 50 | 2020 |
| 5 | Essentia Biosciences | Essentia Biosciences develops cell therapies, gene technology drugs, and medical devices. | Biotech | Haidian, China | Seed | $14.3M | 2026-01-01 | $14.3M | BioVenture, Haitang Fund, Beijing Molecular Technology | 1 to 10 | 2021 |
Table 2. BioVenture portfolio companies: the 5 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 10% | 1 | AusperBio |
| 2 | Med-Fine Capital | Venture capital firm | Shanghai, China | 2 | 10% | 2 | Degron Therapeutics, AccuPulse |
| 3 | Shanghai Biomedical Industrial Equity Investment Fund | Venture capital firm | Huangpu, China | 2 | 10% | 1 | AccuPulse |
| 4 | Haitang Fund | Venture capital firm | Nankai, China | 2 | 10% | 1 | Essentia Biosciences |
| 5 | Hankang Capital | Venture capital firm | Shanghai, China | 1 | 5% | 1 | AusperBio |
| 6 | Genesis Capital | Private equity firm | Central, Hong Kong | 1 | 5% | 1 | AusperBio |
| 7 | Cowin Venture | Angel group | Beijing, China | 1 | 5% | 1 | Degron Therapeutics |
| 8 | Baidu Ventures | Venture capital firm | Beijing, China | 1 | 5% | 1 | Degron Therapeutics |
| 9 | New Alliance Capital | Private equity firm | Shanghai, China | 1 | 5% | 1 | Degron Therapeutics |
| 10 | Gaorong Capital | Venture capital firm | Wangjing, China | 1 | 5% | 1 | Allink Biotherapeutics |
| 11 | Xiamen C&D Emerging Industry Equity Investment | Private equity firm | Xiamen, China | 1 | 5% | 1 | Allink Biotherapeutics |
| 12 | Lanchi Ventures | Venture capital firm | Singapore | 1 | 5% | 1 | Allink Biotherapeutics |
| 13 | Legend Capital | Venture capital firm | Beijing, China | 1 | 5% | 1 | Allink Biotherapeutics |
| 14 | Blue Bay Ventures | Venture capital firm | California City, United States | 1 | 5% | 1 | AccuPulse |
| 15 | WuXi Healthcare Ventures | Venture capital firm | Cambridge, United States | 1 | 5% |
Table 3. BioVenture portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 20 | 95% | $935.4M |
| Biotech | 10 | 48% | $721.1M |
| Software | 5 | 24% | $219.8M |
| Artificial intelligence | 3 | 14% | $204.0M |
| Hardware | 3 | 14% | $106.0M |
Table 4. BioVenture portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. BioVenture portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| China | 20 | 95% |
| United States | 1 | 5% |
Table 6. BioVenture portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. BioVenture portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| August 2026 | 1 | 20% | $120.0M |
| May 2026 | 1 | 20% | $40.0M |
| March 2026 | 1 | 20% | $14.5M |
| January 2026 | 1 | 20% | $14.3M |
| December 2025 | 1 | 20% | $47.0M |
Table 8. BioVenture portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 19% | $188.8M |
| 2025 | 1 | 5% | $47.0M |
| 2024 | 7 | 33% | $49.8M |
| 2023 | 4 | 19% | $42.0M |
| 2022 | 2 | 10% | $20.1M |
| 2021 | 1 | 5% | $84.5M |
Table 9. BioVenture portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 1 | 5% |
| 2020 to 2022 | 5 | 24% |
| 2015 to 2019 | 9 | 43% |
| 2010 to 2014 | 4 | 19% |
| Before 2010 | 2 | 10% |
Table 10. BioVenture portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2 | 11% |
| 11 to 50 | 7 | 39% |
| 51 to 100 | 4 | 22% |
| 101 to 250 | 2 | 11% |
| 251 to 500 | 1 | 6% |
| 501 to 1,000 | 1 | 6% |
| 1,001 to 5,000 | 1 | 6% |
Table 11. BioVenture portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when BioVenture is recorded as one of its investors. On 16 November 2026 that is 21 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 8 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 21 rows: 6 have no round amount, 0 no city and 3 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many BioVenture portfolio companies are on the list?
- 21, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 21 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.